View Pages
Morning Minute: TGT beats, LOW misses, MRNA doubles after melanoma trial news
Target tops estimates, Lowe’s misses revenue, and Moderna jumps after positive Merck-partnered melanoma trial—headlines to watch before Wednesday’s session.
Editorial companion
What stands out
Target beat on both the top and bottom lines while Lowe's missed revenue, and Moderna doubled in the premarket after a late-stage melanoma win alongside Merck, per a Schwab Network morning clip. That mix matters because it juxtaposes tired retail earnings, small sales declines with profit variability, with a single clinical outcome that can vaporize or create huge market moves overnight. For investors the clip is a reminder: earnings season nudges conviction, clinical readouts create jumps, and you need to treat each with a different time horizon.
View Pages
View Pages
View Pages
Bullish Gator Snapshot
Current ratings and signals
Lowe's (LOW)
Bearish
LOW rates Bearish overall. The fundamental read is neutral: the company passes 4 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 3.01); revenue is declining about 3.7% per year; net income is growing about 1.9% per year. The technical picture is bearish: price is 11.4% below the 200-day moving average; 1.5% above the 50-day; the 50/200 relationship is in a Death cross. Sentiment is bearish (composite 28/100), based on 8 news articles from recent coverage.
Merck & Co. (MRK)
Neutral
MRK rates Neutral overall. The fundamental read is neutral: the company passes 4 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 4.45); revenue is growing about 3.1% per year; net income is declining about 45.5% per year. The technical picture is bearish: price is 12.7% above the 200-day moving average; 3.9% below the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 72/100), based on 4 news articles and 5 qualified videos from recent coverage.
Moderna (MRNA)
Neutral
MRNA rates Neutral overall. The fundamental read is neutral: the company passes 1 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 13.60); revenue is declining about 52.3% per year. The technical picture is bullish: price is 152.7% above the 200-day moving average; 19.1% above the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bearish (composite 28/100), based on 5 news articles, 1 TV segment, and 8 qualified videos from recent coverage.
Target Corporation (TGT)
Neutral
TGT rates Neutral overall. The fundamental read is neutral: the company passes 3 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 3.20); revenue is declining about 1.4% per year; net income is growing about 12.8% per year. The technical picture is bearish: price is 12.6% above the 200-day moving average; 5.3% below the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 78/100), based on 5 news articles from recent coverage.